Evidence map›Paper›PMID 39632730›Full record

ArticleAnnals of medicine2025

Evaluating the efficacy and safety of polyglycolic acid-loading mitomycin nanoparticles in inhibiting the scar proliferation after glaucoma filtering surgery.

Tao Li, Juan Tang, Changfen Li, Guogang Liu, Ying Li, Shanlan Guo, Qilin Fang, Jing Li, Xing Qi, Xingde Liu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tao LiDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Juan TangDepartment of Ophthalmology, Key Laboratory of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Changfen LiDepartment of Pathology, Zi Yang Central Hospital, Sichuan, China.
Guogang LiuDepartment of Dermatology, Zi Yang Central Hospital, Sichuan, China.
Ying LiDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Shanlan GuoDepartment of Pathology, Zi Yang Central Hospital, Sichuan, China.
Qilin FangDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Jing LiDepartment of Pathology, Zi Yang Central Hospital, Sichuan, China.
Xing QiDepartment of Experimental Medicine, Zi Yang Central Hospital, Sichuan, China.
Xingde LiuDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Juan DuDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Dan ZhangDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Silun XiongDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Jiaqian LiDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Yueyue TanDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Biao LiDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.
Chuanqiang DaiDepartment of Medical Education, Zi Yang Central Hospital, Sichuan, China.
Qinqin ZhangDepartment of Medical Education, Zi Yang Central Hospital, Sichuan, China.
Jiaman LiDepartment of Anesthesia Operation Center, Zi Yang Central Hospital, Sichuan, China.
Xiaoli WuDepartment of Ophthalmology, Zi Yang Central Hospital, Sichuan, China.ORCID 0009-0006-2783-906X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo prepare a polyglycolic acid-loaded mitomycin drug (MMC-ATS-@PLGA) to inhibit scar proliferation after glaucoma filtering surgery (GFS)

methodsWe first detected the physicochemical properties of MMC-ATS-@PLGA. Next, we tested the biosafety of MMC-ATS-@PLGA

resultsIn this study, we synthesized a new type of nanomedicine (MMC-ATS-@PLGA) with good stability and biocompatibility for inhibiting scar proliferation after GFS. The break-up time (BUT), Schimer test and intraocular pressure changes in GFS rabbits before and after treatment with MMC-ATS-@PLGA were not significantly different. Three weeks after GFS, the MMC-ATS-@PLGA group displayed significant decreases in nuclear volume, corneal cell oedema, type I and III collagen fibre expression, normal organelle morphology and collagen fibre arrangement. Compared with those in the FML and MMC groups, the α-SMA, CTGF and type III collagen fibres in the MMC-ATS-@PLGA group decreased more significantly, indicating that MMC-ATS-@PLGA can effectively inhibit the expression of these inflammatory factors during the inhibition of scar proliferation after GFS.

conclusionWe successfully synthesized MMC-ATS-@PLGA, which could effectively inhibit scar proliferation after GFS

Indexed as

CicatrixFiltering SurgeryGlaucomaIntraocular PressureMitomycinNanoparticlesAnimalsCell ProliferationMalePolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerRabbitsMitomycinPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymerglaucoma filtering surgeryinflammationMitomycinPLGAscar proliferation

Identifiers

PMID39632730
PMCPMC11622377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.